3 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
ASCVD or ASCVD risk ... ASCVD or ASCVD risk ... SGLT2 #inhibitors #EBM ... #trial #visualabstract ... #table #CVD #CKD
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

CONCLUSIONS:
Among patients with heart failure and a
fraction, the risk ... was lower among ... Dapagliflozin #hfref #chf ... #visualabstract ... #ebm
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
metabolic equivalent able ... disease b) CHF ... ASA class If ... event, follow ACC algorithm ... Stable patients